Pozelimab
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
CHAPLE Disease
Conditions
CHAPLE Disease
Trial Timeline
Mar 6, 2026 → Jan 31, 2030
NCT ID
NCT07142343About Pozelimab
Pozelimab is a approved stage product being developed by Regeneron Pharmaceuticals for CHAPLE Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07142343. Target conditions include CHAPLE Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05232110 | Pre-clinical | Completed |
| NCT06003881 | Pre-clinical | Completed |
| NCT07142343 | Approved | Recruiting |
| NCT07230834 | Phase 1 | Recruiting |
| NCT04491838 | Phase 1 | Completed |
| NCT04209634 | Phase 2/3 | Completed |